AMENDMENT AGREEMENTAmendment Agreement • August 13th, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Colorado
This AMENDMENT AGREEMENT (this “Amendment”), by and between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and Patrick Wheeler (“Executive”) is effective as of June 13, 2013 (the “Effective Date”).
ARISTA PLACEARCA Biopharma, Inc. • August 13th, 2013 • In vitro & in vivo diagnostic substances
Arista Place, LLC (Landlord) agrees to a continuation of the Term of your lease for an additional three (3) month period. The financial terms presently applied to the ARCA (Tenant) lease obligations will remain the same during this additional three (3) month term.
ContractARCA Biopharma, Inc. • August 13th, 2013 • In vitro & in vivo diagnostic substances
When countersigned by Medtronic, this letter shall serve as a permanent waiver of Medtronic’s rights under Section 8.2 (f), and ARCA’s rights under Section 8.3 (e) of the above-referenced Agreement.
AMENDMENT AGREEMENTAmendment Agreement • August 13th, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Colorado
This AMENDMENT AGREEMENT (this “Amendment”), by and between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and Christopher D. Ozeroff (“Executive”) is effective as of June 13, 2013 (the “Effective Date”).
AMENDMENT AGREEMENTAmendment Agreement • August 13th, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Colorado
This AMENDMENT AGREEMENT (this “Amendment”), by and between ARCA biopharma, Inc., a Delaware corporation (the “Company”), and Michael R. Bristow (“Executive”) is effective as of June 13, 2013 (the “Effective Date”).
